Conv. Plasma
Nigella Sativa

All molnupiravir studies
Meta analysis
study COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Combined death/ventilati.. -12% Improvement Relative Risk Hospitalization -17% Molnupiravir for COVID-19  Yip et al.  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 88,962 patients in China (February - March 2022) Higher hospitalization with molnupiravir (not stat. sig., p=0.062) Yip et al., Clinical Infectious Diseases, May 2022 Favors molnupiravir Favors control

Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients

Yip et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac687 (date from preprint)
May 2022  
  Source   PDF   All   Meta
Propensity score weighted retrospective of 93,883 outpatients in Hong Kong, 5,808 treated with molnupiravir and 4,921 treated with paxlovid, showing higher hospitalization and higher combined mortality/mechanical ventilation/ICU admission with molnupiravir, without statistical significance; and lower hospitalization and combined mortality/mechanical ventilation/ICU admission with paxlovid, statistically significant only for hospitalization.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Chamod, Hadj Hassine, Huntsman, Marikawa, Swanstrom, Waters, Zhou, Zibat. Multiple analyses have identified variants potentially created by molnupiravir Fountain-Jones, Kosakovsky Pond, Sanderson,
Study covers paxlovid and molnupiravir.
combined death/ventilation/ICU, 12.0% higher, HR 1.12, p = 0.66, treatment 53 of 5,808 (0.9%), control 151 of 83,154 (0.2%), propensity score weighting, Cox proportional hazards, day 30.
risk of hospitalization, 17.0% higher, HR 1.17, p = 0.06, treatment 437 of 5,808 (7.5%), control 1,322 of 83,154 (1.6%), propensity score weighting, Cox proportional hazards, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yip et al., 24 May 2022, retrospective, placebo-controlled, China, peer-reviewed, 11 authors, study period 16 February, 2022 - 31 March, 2022. Contact:
This PaperMolnupiravirAll
PhD Terry Cheuk-Fung Yip, MD Chung-Yan Lui, BSc Mandy Sze-Man Lai, MD Wai-Sun Wong, MPhil Yee-Kit Tse, Hon-Ming Bosco, MD Ma, MD Elsie Hui, MFM Maria Kw Leung, Henry Lik-Yuen, MD Chan, MD Shu-Cheong Hui, Lai-Hung Grace, MBChB Wong
Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients
Ahmad, Batool, Ain, Kim, Choi, Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations, Int J Mol Sci
Balint, Voros-Horvath, Szechenyi, Omicron: increased transmissibility and decreased pathogenicity, Signal Transduct Target Ther
Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Bhimraj, Morgan, Shumaker, Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19, Clin Infect Dis
Bloomberg, Hong Kong's Nursing Homes Are Unvaccinated Hotbeds of Covid
Cheung, Fung, Chow, Tung, Structured data entry of clinical information for documentation and data collection, Stud Health Technol Inform
Consortium, Whost, Pan, Peto, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med
Dal-Re, Becker, Bottieau, Holm, Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach, Lancet Infect Dis
De Anda, Johnson, Pedley, Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply, N Engl J Med
Gandhi, Malani, Rio, COVID-19 Therapeutics for Nonhospitalized Patients, JAMA
Hammond, Leister-Tebbe, Gardner, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med
Hksar Government, Overall first-dose COVID-19 vaccination rate of RCHEs and RCHDs rises to 84 per cent on 11
Hui, Zumla, Advances in the epidemiology, clinical features, diagnosis, clinical management and prevention of coronavirus disease 2019, Curr Opin Pulm Med
Jo, Kim, Radnaabaatar, Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in Korea, Epidemiol Health
Kabinger, Stiller, Schmitzova, Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat Struct Mol Biol
Krammer, SARS-CoV-2 vaccines in development, Nature
Lui, Yip, Wong, Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study, Clin Infect Dis
Najjar-Debbiny, Gronich, Weber, Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients, Clin Infect Dis
Pfizer, Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR
Roth, Emmons-Bell, Alger, Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic, JAMA Netw Open
Saravolatz, Depcinski, Sharma, Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs, Clin Infect Dis
Thorlund, Sheldrick, Meyerowitz-Katz, Singh, Hill, Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial, Am J Trop Med Hyg
Vangeel, Chiu, Jonghe, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res
Wong, Au, Lau, Lau, Cowling et al., community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study, doi:10.1101/2022.05.26.22275631
Yip, Wong, Lui, Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19, Hepatology
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop